Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease that can have a devastating impact on those affected and their loved ones. It is the fastest growing neurological disease and more than 10 million people worldwide are living with Parkinson’s disease today.1,2
Parkinson’s disease is a complex disease associated with both motor and non-motor symptoms that cause disability and impact quality of life. Symptoms can vary widely between individuals and disease progression is not predictable, in which symptoms can develop gradually over time or suddenly. Clinical diagnosis of Parkinson’s disease is late in the disease course and currently based only on motor symptoms, with non-motor symptoms often preceding diagnosis by up to 20 years.
By the time of motor symptom onset, individuals have already lost more than 50 percent of the nerve cells that make dopamine, highlighting the unmet need for earlier diagnosis and treatments that slow or stop the progression of Parkinson's disease.3 Currently, there are no such treatment options approved for Parkinson’s disease.
Roche has helped thousands of individuals living with Parkinson’s disease over the past 50 years. We remain committed to evaluating multiple approaches that could potentially slow or stop disease progression and disability in people with Parkinson’s disease by developing treatments that target the underlying biology and drivers of neurodegeneration.
References
Parkinson’s UK. What is Parkinson’s?
Parkinson’s Foundation. Statistics.
Noyce AJ, Lees AJ, Schrag A-E. J Neurol Neurosurg Psychiatry 2016;87:871–878
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.